Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Regen Biopharma ( (RGBP) ) has shared an update.
On July 28, 2025, Regen Biopharma, Inc. entered into a securities purchase agreement with CFI Capital LLC, resulting in the issuance of a 6% convertible promissory note valued at $130,000. This agreement allows CFI to convert the note into common stock at a discounted rate, potentially impacting Regen Biopharma’s stock market activity and investor relations.
More about Regen Biopharma
Regen Biopharma, Inc. operates in the biotechnology industry, focusing on developing innovative treatments and therapies. The company is involved in the research and development of regenerative medicine and immunotherapy solutions.
Average Trading Volume: 55,153
Technical Sentiment Signal: Sell
Current Market Cap: $1.58M
Find detailed analytics on RGBP stock on TipRanks’ Stock Analysis page.